Back to Search Start Over

Targeted inhibition of β-catenin alleviates airway inflammation and remodeling in asthma via modulating the profibrotic and anti-inflammatory actions of transforming growth factor-β1.

Authors :
Huo, Rujie
Tian, Xinli
Chang, Qin
Liu, Dai
Wang, Chen
Bai, Jingcui
Wang, Runjuan
Zheng, Guoping
Tian, Xinrui
Source :
Therapeutic Advances in Respiratory Disease; 2/2/2021, p1-14, 14p
Publication Year :
2021

Abstract

Background: TGF-β<subscript>1</subscript> is a key cytokine involved in both airway inflammation and airway remodeling in asthma because of its anti-inflammatory and profibrotic effect. In our previous study, we found that knockdown of cytosolic β-catenin alleviated the profibrogenic effect of TGF-β<subscript>1</subscript> without influencing its anti-inflammatory effect. However, the exact role of targeting β-catenin in asthma is not yet fully demonstrated. In the present study, we investigated the effect and mechanism of targeting β-catenin in OVA-challenged asthmatic rats with airway inflammation and remodeling features. Methods: We integrated experimental asthma model and asthma related cell model to explore the effect of targeting β-catenin on airway inflammation and remodeling of asthma. Results: Blocking β-catenin with ICG001, a small molecule inhibitor of β-catenin/TCF via binding to cAMP-response elementbinding protein, attenuated airway inflammation by increasing levels of anti-inflammation cytokines IL-10, IL-35 and decreasing levels of T helper (Th)2 cells and Th17 cytokine. Suppressing β-catenin by ICG001 inhibited airway remodeling via reducing the level of TGF-β<subscript>1</subscript> and the expressions of Snail, MMP-7, MMP-9 and, up-regulating expression of E-cadherin, down-regulating expressions of α-SMA and Fn. Inhibition of β-catenin with ICG001 suppressed TGF-β<subscript>1</subscript> induced proliferation and activation of CCC-REPF-1, blocked TGF-β<subscript>1</subscript> induced epithelial–mesenchymal transition (EMT) of RLE-6TN. Conclusion: Blockade of β-catenin/TCF not only prevents TGF-β<subscript>1</subscript> induced EMT and profibrogenic effects involved in pathological remodeling of airway, but also alleviates airway inflammation in asthma by balancing pro-inflammatory and anti-inflammatory cytokine. In conclusion, targeting β-catenin specifically via inhibition of β-catenin/TCF might be a new therapeutic strategy for asthma. The reviews of this paper are available via the supplemental material section. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
17534658
Database :
Complementary Index
Journal :
Therapeutic Advances in Respiratory Disease
Publication Type :
Academic Journal
Accession number :
148495278
Full Text :
https://doi.org/10.1177/1753466620981858